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Adoptive autoimmunity has been proposed as
the mechanism of post-allogeneic hematopoietic
stem cell transplantation (HSCT) disease which
develops after cell transfer from a donor with an
autoimmune condition to a recipient without this
condition. Hyperthyroidism after HSCT is a rare
complication.1 We report a case of acquired hyper-
thyroidism with thyrotoxicosis due to immune
thyroiditis in a patient who received an allogeneic
transplant from a donor with Graves’ disease.
In contrast, we report improvement in the
condition of a patient with Sjögren’s syndrome
after allogeneic HSCT. The basis of our treatment
of autoimmune disease (AID) was the eradica-
tion of autoreactive lymphocytes by immunoab-
lative conditioning and the correction of the
dysregulated immune balance by providing im-
mune cells (newly developed lymphocytes from
the HSCT).2,3 Human leukocyte antigen (HLA)-
matched allogeneic HSCT may thus cure an au-
toimmune disorder by transferring numerous
donor non-HLA autoimmune disease-resistant
cells that exert a graft versus autoimmunity (GVA)
effect.
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Hematopoietic stem cell transplantation (HSCT) can either cause or eliminate autoimmune disease. Here,
we report two cases. One was a 33-year-old woman with myelodysplastic syndrome (refractory anemia)
who received bone marrow transplantation from her human leukocyte antigen (HLA)-identical sister who
had a history of Graves’ disease. Antithyroid antibodies, including antimicrosomal antibody and antithy-
roglobulin antibody, appeared 4 months after transplantation. Clinical hyperthyroidism appeared 7 months
after transplantation, and a hypothyroid state was noted 2 months later. The other case was a 50-year-old
woman with Sjögren’s syndrome and hypothyroidism who was diagnosed with peripheral T cell non-
Hodgkin’s lymphoma. She received allogeneic peripheral blood stem cell transplantation (PBSCT) from
her histocompatible sister owing to only partial response to traditional chemotherapy. Cure of lymphoma
and remission of Sjögren’s syndrome was noted 4 years after PBSCT. These two illustrative cases, one of 
acquisition of hyperthyroidism and the other of remission of Sjögren’s syndrome after transplantation,
highlights that HSCT can induce adoptive autoimmune disease or cure coincidental autoimmune disease.
Donor selection and attentive monitoring is required in such circumstances. [J Formos Med Assoc
2007;106(9):779–783]
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In 1993, this 33-year-old woman had myelodys-
plastic syndrome (refractory anemia) with dif-
fuse petechiae and general malaise. The bone
marrow examination showed normal cellularity
with marked dyserythropoiesis but without ex-
cess of blasts. Cytogenetic study revealed a nor-
mal karyotype. On June 2, 1994, she underwent
allogeneic bone marrow transplantation (BMT)
(3.37×108 mononuclear cells/per kg body weight)
after conditioning with busulfan (4 mg/kg/day
for 4 days) and cyclophosphamide (60 mg/kg/day
for 2 days). Cyclosporin and methotrexate were
used for graft-versus-host disease (GVHD) pro-
phylaxis. She achieved full donor chimerism after
the transplant.
The donor was her HLA-identical sister
(A24(9), A11, Bw60(40), Bw6, Cw10(3), DR9,
DRw53, DQw6(1), DQw3). In 1993, Graves’ dis-
ease was diagnosed with the presentation of 
intermittent palpitations, hand tremors, exoph-
thalmos, irritability, and oligomenorrhea. She
underwent subtotal thyroidectomy for better dis-
ease control and then was lost to follow-up so that
no thyroid function test or pathologic results were
available. In December 1993, weight gain (4–5 kg
in 2 months), cold intolerance, general malaise,
and abnormal thyroid hormone values (thyroxin
[T4] < 2 µg/dL [normal, 4.5–12 µg/dL], triiodothy-
roxin [T3]: 39.9 ng/dL [normal, 80–200 ng/dL],
thyroid-stimulating hormone [TSH] >100µIU/mL
[normal, 0.35–5 µIU/mL], and high titers of 
antithyroglobulin antibody [> 1:20,480 + ] and
antimicrosomal antibody [> 1:20,480 + ]) were
noted. Her clinical symptoms and signs subsided
after treatment with levothyroxin (100 µg/day).
In June 1994, euthyroid status (T4, 14.5 ug/dL;
T3, 180 ng/dL; TSH, 0.45 uIU/mL) was achieved.
She served as a BMT donor for her younger sister
on June 2, 1994. No T cell depletion was per-
formed. She remained euthyroid under levothy-
roxin replacement therapy.
The patient was euthyroid, both clinically and
immunologically, before transplantation. Four
months later, she remained clinically euthyroid
but had developed detectable levels of antithy-
roglobulin antibody (> 1:20,480 + ) and antimi-
crosomal antibody (> 1:20,480 + ). Examination
of her thyroid gland was unremarkable. Seven
months after BMT, she had clinical hyperthy-
roidism (palpitations, tachycardia, tremor of the
hands, heat intolerance) and her serum TSH
level was 0.07 µIU/mL, T3 was 224 ng/dL, and T4
was 15.2 µg/dL. Graves’ disease was impressed
and she received carbimazole (10 mg/day). Three
months later, she experienced weight gain, gen-
eral malaise, and cold intolerance. Goiter (grade 0)
was noted and hypothyroidism was detected 
(T4, 5.82 µg/dL; T3, 136 ng/dL; TSH, 12 µIU/mL)
with persistently elevated thyroid antibodies
(Table 1). She was then treated with levothyroxin
(100 µg/day) for 2 years and remained euthyroid
afterwards.
Case 2
In 1994, Sjögren’s syndrome was diagnosed in a
50-year-old woman with xerostomia and kerato-
conjunctivitis sicca. Serologic signs of autoim-
mune disease with positive antinuclear antibody
(ANA, 1:5120 + speckle), rheumatoid factor (RF,
1:160 + ), and decreased complement levels (C3,
60 mg/dL; C4, 10.9 mg/dL) were found. Schirmer’s
eye test revealed dry eyes (3 mm in the right eye
and 4 mm in the left eye). Six months later, hy-
pothyroidism (T4, 3.74 µg/dL; T3, 26.8 ng/dL;
TSH, 7.56 µIU/mL) was noted. She was treated
with levothyroxin (100 µg/day).
In 2000, a mediastinal mass with the presen-
tation of dry cough and mild dyspnea was found.
The pathology revealed T cell non-Hodgkin’s
lymphoma with involvement of the mediastinum
and lymph nodes on both sides of the diaphragm.
She received one course of CNOP4 (cyclophos-
phamide 750mg/m2 on D1, novantrone 20mg/m2
on D1, oncovin 2 mg on D1 and methylpred-
nisolone 80 mg/day on D1–D5) with a poor re-
sponse, and three courses of ESHAP5 (etoposide
40 mg/m2 on D1–D4, Ara-C 2 g/m2 on D5, cis-
platin 25 mg/m2 on D1–D4 and methylpred-
nisolone 80 mg/day on D1–D5) with a partial
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response. Salvage chemotherapy with BOMES6
(1,3-bis[2-chloroethyl]-1-nitrosourea [BCNU]
65 mg/m2 on D1–D2, oncovin 2 mg on D1,
methylprednisolone 200 mg/day on D1–D7,
etoposide 50 mg/m2 on D1–D5, and methotrex-
ate 1500 mg/m2 on D15) was given. During this
period, she continued to complain of intermit-
tent arthralgia, dry eyes and dry mouth. Episodes
of autoimmune hemolytic anemia with serologic
signs of active autoimmune disease were noted.
In April 2001, she underwent allogeneic PBSCT
(16.59 × 106 CD 34+ cells/per kg body weight)
after conditioning with total body irradiation
(1200 cGy/8 fractions) and cyclophosphamide
(48 mg/kg/day for 2 days). The donor was her
HLA-identical brother (A2, A11.1, Bw60(40),
Bw55(22), Bw6, Cw1, Cw7, DRw8, DRw12(5),
DQw6.1(1), DQw7(3)3). Engraftment was
achieved with full donor chimerism, and mild
skin GVHD (grade I) developed. Steroid was dis-
continued afterwards. Her serologic values (ANA
1:40 + with negative RF and normal complement
values) normalized (Table 2), and the clinical
signs of Sjögren’s disease improved dramatically.
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Table 1. Results of thyroid function and autoantibody testing before and after allogeneic bone marrow
transplantation (BMT) in a 33-year-old woman with myelodysplastic syndrome and her donor with
a history of Graves’ disease
Thyroid antibodies†
Time of test TSH* (µIU/mL) T4* (µg/dL) T3* (ng/dL)
Microsomal Thyroglobulin
Donor
At BMT 12 5.82 180 > 1:20,480 + > 1:20,480 +
Patient 
Pre-BMT 0.88 8.54 118 Negative Negative
Post-BMT
4 mo 1.8 9.9 179 > 1:20,480 + > 1:20,480 +
7 mo 0.07 15.2 224 1:20,480 + 1:20,480 +
10 mo 12 5.82 224 1:20,480 + 1:20,480 +
2 yr 0.96 11.3 150 1:20,480 + 1:20,480 +
11 yr 2.24 8.34 119 1:20,480 + 1:20,480 +
*Normal values are 0.35–5mIU/mL for TSH, 4.5–12mg/dL for T4, and 80–200 ng/dL for T3; †thyroid antibodies of the donor before BMT
were microsomal 1:20,480 + and thyroglobulin 1:20,480 + . TSH = thyroid-stimulating hormone; T4 = thyroxin; T3 = triiodothyroxin.
Table 2. Serial change in autoimmune profile before and after allogeneic peripheral blood stem cell
transplantation (PBSCT) in a 50-year-old woman with Sjögren’s syndrome and hypothyroidism
Time of test ANA RA/RF C3 C4 T3 T4 TSH
Data at diagnosis 1:5120 + speckle 1:160 + 60.0 10.9 26.8 3.74 7.56
Post CT and before PBSCT 1:2560 + homogeneous 28.1 IU/mL 64.1 14.8 32.9 1.12 0.86
Post PBSCT
1 yr 1:320 + speckle < 20 ND ND 81.6 7.58 2.07
2 yr 1:160 + speckle < 20 ND ND 91.7 7.12 2.59
4 yr 1:40 + speckle < 20 95.7 29 ND ND ND
4.5 yr 1:40 + speckle < 20 98.5 18.4 98.7 7.24 2.39
*Normal values are < 1:320 + (homogeneous) and < 1:640 + (speckle) for ANA, < 20 IU/mL for RA (nephelometry), < 1:40+ for RF
(rheumatoid arthritis hemagglutination assay titer), 81.61–118.41 mg/dL for C3 quantitation, 27.45±10.72 mg/dL for C4 quantitation,
80–200 ng/dL for T3, 4.5–12mg/dL for T4, 0.35–5mIU/mL for TSH. ANA = antinuclear antibody; RA = rheumatoid arthritis; RF =
rheumatoid factor; T3 = triiodothyroxin; T4 = thyroxin; TSH = thyroid-stimulating hormone; CT = chemotherapy; ND = no data.
Cure of lymphoma and remission of Sjögren’s
syndrome were noted at her 4-year follow-up visit.
Discussion
The basis for using high-dose immunosuppres-
sive therapy and HSCT to treat AID is the finding
that HSCT is effective in animal models of AID7
and in patients who, though treated for malignant
disease with autologous HSCT, achieved long-
term remission of coincidental AID.8–11 Gradual
progressive development of donor-derived im-
munity (immune reconstitution) was noted after
allogeneic HSCT.12
Adoptive autoimmunity after allogeneic HSCT
develops generally because donor autoreactive B
cell clones (“renegade” clones) are held in check
by a combination of regulatory and suppressive
mechanisms triggered by post-HSCT imbalances
in the recipient. Case reports document the fact
that post-HSCT hyperthyroidism is much rarer than
post-HSCT hypothyroidism.13–15 Because autoim-
mune thyroid disease is common in females of
childbearing age, the etiology of post-transplant
hyperthyroidism in our patient needed to be
evaluated. Table 1 shows that she was euthyroid,
both clinically and immunologically, before trans-
plantation. No obvious viral infection or offend-
ing drugs were found. All bone marrow samples
examined after HSCT were of donor origin, and
the donor had Graves’ disease, suggesting that
adoptive autoimmunity was the etiologic mecha-
nism. The likely mechanism involved a clone of
donor lymphocytes programmed to produce thy-
roid stimulating or thyroid blocking autoantibod-
ies and a destructive autoimmune process that
ended in the development of hypothyroidism.
The risk of adoptive autoimmunity does not con-
traindicate the use of HSCT therapeutically for
the control of AID. However, this issue should be
considered during donor selection, and attentive
and careful immunologic monitoring is required.
The course of AID and response to therapy
following allogeneic HSCT are occasionally diffi-
cult to judge. Cure of AID may be defined as a
long-term and treatment-free clinical remission
with normalization of autoimmune profiles and
restoration of normal immunity. The strategy of
eradicating pre-existent autoimmune disorders is
(1) myeloablative conditioning to achieve im-
munosuppression and (2) replacement or ma-
nipulation of hematopoietic stem cells to achieve
a GVA effect.16–18 In our patient with Sjögren’s
syndrome, the indication for this treatment was
not the autoimmune disease, but rather the 
presence of concomitant aggressive lymphoma.
Previous studies revealed short-lived and tempo-
rary response to autologous transplantation with
unfavorable outcome in patients with primary
Sjögren’s syndrome,19–21 even when the hemato-
logic malignancy was controlled. Our patient ex-
perienced partial arthralgia relief but no dry eye
relief after chemotherapy. The gradual improve-
ment in symptoms after allogeneic transplanta-
tion and their subsidence months later suggest
that the GVA effect played an important role in
the “cure” of Sjögren’s syndrome in this patient.
Although remission has been durable and com-
plete in the few patients with coincidental AID
who have been treated with HSCT, transplant-
related morbidity, mortality, and long-term com-
plications should still be borne in mind.
In conclusion, HSCT can incite adoptive AID
or cure coincidental AID. The immunosuppres-
sive regimens may eliminate or effectively reduce
the level of autoreactive immunocompetent cells,
and the transplanted stem cells may bypass the
initial self-intolerance to restore normal immu-
nity. Thus, HSCT is a feasible and effective treat-
ment for severe and refractory AID. As for adoptive
autoimmunity, the picture is incomplete and fur-
ther studies are needed.
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